People · Operator
Named in public records as an officer, director or promoter · active 2018–2021 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Antios Therapeutics Inc. | — | Pharmaceuticals | Series C | $126.4M | $1.7B | 2018 |
Abel De La Rosa at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Abel De La Rosa on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Craig Gordon | 1 | 6 |
| Gregory Mayes | 1 | 5 |
| NICOLE VITULLO | 1 | 4 |
| Benjamin Rovinski | 1 | 3 |
| Iyona Rajkomar | 1 | 3 |
| DAVID CANNER | 1 | 2 |
| Scott Morenstein | 1 | 2 |
| Idean Marvasty | 1 | 2 |
| Patrick Higgins | 1 | 2 |
| Douglas Mayers | 1 | 1 |
| Nicole Vitulio | 1 | 1 |
| Douglas Lin Mayers | 1 | 1 |
| Henry Lin Chen | 1 | 1 |
| Tamra Adams | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.